Median duration of psychotropic medication use before baseline scan was short (Table 1). At the time of the first scan, patients were variously receiving neuroleptics (typical[6, schizophrenia; 9, affective psychosis], atypical [2, schizophrenia; 5, affective psychosis], or both [3, schizophrenia; 0, affective psychosis]); mood stabilizers (lithium carbonate [1, schizophrenia; 5, affective psychosis], valproate sodium [3, schizophrenia; 5, affective psychosis]); or only drugs other than neuroleptics and mood stabilizers (1, schizophrenia; 1, affective psychosis). Typical or atypical neuroleptic status for 1 schizophrenic patient was unknown due to enrollment in a double-blinded olanzapine-haloperidol crossover protocol. Between scans, hospital records and self-reports indicated patients received neuroleptics (typical [1, schizophrenia; 0, affective psychosis], atypical [9, schizophrenia; 5, affective psychosis], or both [0, schizophrenia; 1, affective psychosis]); mood stabilizers exclusively (lithium [3, schizophrenia; 5, affective psychosis], valproate sodium [5, schizophrenia; 7, affective psychosis]); drugs other than neuroleptics or mood stabilizers (1, schizophrenia; 1, affective psychosis); or no drugs or discontinued use of medication (2, schizophrenia; 1, affective psychosis). The medication status for 1 affective psychosis patient was unknown.